沙库巴曲缬沙坦钠片对缺血性心肌病心力衰竭患者的影响分析

Analysis of the effect of sacubitril valsartan sodium tablets on patients with ischemic cardiomyopathy and heart failure

目的分析缺血性心肌病心力衰竭患者采取沙库巴曲缬沙坦钠片治疗的效果。方法选取120例缺血性心肌病心力衰竭患者,以随机数字表法分为观察组(n=60,采取常规药物联合沙库巴曲缬沙坦钠片治疗)和对照组(n=60,采取常规药物治疗)。比较两组的临床疗效、心功能[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDd)]、血清N末端脑钠肽前体(NT-proBNP)水平、营养状态[白蛋白(ALB)、前白蛋白(PA)]及不良反应发生情况。结果观察组的治疗总有效率93.33%显著高于对照组的80.00%(P<0.05)。治疗后,两组LVEF、LVEDd、NT-proBNP水平均有所改善,且观察组LVEF、LVEDd、NT-proBNP水平分别为(52.96±4.18)%、(51.20±4.63)mm、(1045.33±218.91)pg/ml,均优于对照组的(48.50±4.06)%、(55.82±4.16)mm、(2561.27±308.96)pg/ml(P<0.05)。治疗后,两组ALB、PA水平均提升,且观察组ALB(38.11±2.04)g/L、PA(190.52±11.17)mg/L高于对照组的(36.76±2.30)g/L、(185.30±12.59)mg/L(P<0.05)。两组的不良反应发生率比较并未存在明显差异(P>0.05)。结论在缺血性心肌病心力衰竭患者的临床治疗中,采取沙库巴曲缬沙坦钠片治疗取得的效果更为理想,能够有效改善患者的心功能和营养状态,对预后改善起到促进作用。

Objective To analyze the effect of sacubitril valsartan sodium tablets on patients with ischemic cardiomyopathy and heart failure.Methods A total of 120 patients with ischemic cardiomyopathy and heart failure were selected and divided into an observation group(n=60,treated with conventional drugs combined with sacubitril valsartan sodium tablets)and a control group(n=60,treated with conventional drugs)by random number table method.Both groups were compared in terms of clinical efficacy,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDd)],serum N-terminal pro-brain natriuretic peptide(NT-proBNP)level,nutritional status[albumin(ALB),prealbumin(PA)],and the occurrence of adverse reactions.Results The total effective rate of 93.33%in the observation group was significantly higher than 80.00%in the control group(P<0.05).After treatment,the levels of LVEF,LVEDd and NT-proBNP were improved in both groups;the levels of LVEF,LVEDd and NT-proBNP in the observation group were(52.96±4.18)%,(51.20±4.63)mm and(1045.33±218.91)pg/ml,which were better than(48.50±4.06)%,(55.82±4.16)mm and(2561.27±308.96)pg/ml in the control group(P<0.05).After treatment,the levels of ALB and PA were increased in both groups;the observation group had ALB of(38.11±2.04)g/L and PA of(190.52±11.17)mg/L,which were higher than(36.76±2.30)g/L and(185.30±12.59)mg/L in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the clinical treatment of patients with ischemic cardiomyopathy and heart failure,the effect of sacubitril valsartan sodium tablets is more ideal,which can effectively improve the cardiac function and nutritional status of patients,and promote the improvement of prognosis.